<?xml version="1.0" encoding="UTF-8"?>
<p>In addition, several CDKIs were designed bearing substituted urea moiety
 <xref rid="CIT0019" ref-type="bibr">
  <sup>19–22</sup>
 </xref>. The importance of this moiety in the formation of hydrogen bonding network with the kinase domain which improves inhibitory activities against CDKs was discussed in several reports
 <xref rid="CIT0019" ref-type="bibr">
  <sup>19</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0021" ref-type="bibr">
  <sup>21</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0022" ref-type="bibr">
  <sup>22</sup>
 </xref>. Honma et al. investigated the inhibitory activities of several diaryl urea derivatives against CDK-4
 <sup>19</sup>. The results revealed higher kinase inhibitory activity for the derivatives with the bulky aryl moiety when substituted with H-bond donner (HB
 <sub>D</sub>)/acceptor (HB
 <sub>A</sub>) groups. Among these derivatives, compound 
 <bold>6</bold> with the bulky 7-hydroxynaphthalen-1-yl moiety inhibited CDK-4 with an IC
 <sub>50</sub> value of 7.6 μM, 
 <xref ref-type="fig" rid="F0002">Figure 2</xref>. Compound 
 <bold>7</bold> (CDKi 277, 
 <xref ref-type="fig" rid="F0002">Figure 2</xref>) is also a thiazolyl urea derivative which exhibited potent ATP competitive inhibitory activity against CDKs 1, 2, and 5 with IC
 <sub>50</sub> values of 8, 4, and 5 nM, respectively
 <xref rid="CIT0020" ref-type="bibr">
  <sup>20</sup>
 </xref>.
</p>
